New! View global litigation for patent families

US20010056255A1 - Effect of electric field and ultrasound for transdermal drug delivery - Google Patents

Effect of electric field and ultrasound for transdermal drug delivery Download PDF

Info

Publication number
US20010056255A1
US20010056255A1 US09528506 US52850600A US2001056255A1 US 20010056255 A1 US20010056255 A1 US 20010056255A1 US 09528506 US09528506 US 09528506 US 52850600 A US52850600 A US 52850600A US 2001056255 A1 US2001056255 A1 US 2001056255A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
ultrasound
skin
transdermal
electric
transport
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09528506
Inventor
Joseph Kost
Uwe Pliquett
Samir Mitragotri
Robert Langer
James Weaver
Original Assignee
Joseph Kost
Uwe Pliquett
Mitragotri Samir S.
Langer Robert S.
Weaver James C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14507Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/1451Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
    • A61B5/14514Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0047Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0092Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/0404Electrodes for external use
    • A61N1/0408Use-related aspects
    • A61N1/0412Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/0404Electrodes for external use
    • A61N1/0408Use-related aspects
    • A61N1/0412Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • A61N1/0416Anode and cathode
    • A61N1/042Material of the electrode
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/0404Electrodes for external use
    • A61N1/0408Use-related aspects
    • A61N1/0428Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs

Abstract

Transdermal transport of molecules during sonophoresis (delivery or extraction) can be further enhanced by application of an electric field, for example, electroporation or iontophoresis. In a preferred embodiment the ultrasound is low frequency ultrasound which induces cavitation of the lipid layers of the stratum corneum (SC). This method provides higher drug transdermal fluxes, allows rapid control of transdermal fluxes, and allows drug delivery or analyte extraction at lower ultrasound intensities than when ultrasound is applied in the absence of an electric field.

Description

  • [0001]
    This is a continuation in part of U.S. Ser. No. 08/574,377 entitled “Chemical and Physical Enhancers and Ultrasound for Transdermal Drug Delivery” filed Dec. 18, 1995 by Mark E. Johnson, Samir S. Mitragotri, Daniel Blankschtein and Robert S. Langer.
  • [0002] The United States government has rights in this invention by virtue of National Institute of Health (NIH grant GM44884) to Robert Langer and Army Office Grant No. DAAL03-90-G0218 to James C. Weaver.
  • BACKGROUND OF THE INVENTION
  • [0003]
    The present invention generally relates to improved methods for drug delivery and measurement of analyte using ultrasound in combination with application of an electric field.
  • [0004]
    Transdermal drug delivery (TDD) offers several advantages over traditional delivery methods including injections and oral delivery. When compared to oral delivery, TDD avoids gastrointestinal drug metabolism, reduces first-pass effects, and provides sustained release of drugs for up to seven days, as reported by Elias, In Percutaneous Absorption: Mechanisms—Methodology-Drag Delivery., Bronaugh, R. L., Maibach, H. 1. (Ed), pp 1-12, Marcel Dekker, New York, 1989. The word “transdermal” is used herein as a generic term. However, in actuality, transport of drugs occurs only across the epidermis where the drug is absorbed in the blood capillaries. When compared to injections, TDD eliminates the associated pain and the possibility of infection. Theoretically, the transdermal route of drug administration could be advantageous in the delivery of many therapeutic proteins, because proteins are susceptible to gastrointestinal degradation and exhibit poor gastrointestinal uptake, proteins such as interferons are cleared rapidly from the blood and need to be delivered at a sustained rate in order to maintain their blood concentration at a high value, and transdermal devices are easier to use than injections.
  • [0005]
    Ultrasound has been shown to enhance transdermal transport of low-molecular weight drugs (molecular weight less than 500) across human skin, a phenomenon referred to as sonophoresis (Levy, J. Clin Invest. 1989, 83, 2974-2078; Langer, R., In “Topical Drug Bioavailability, Bioequivalence, and Penetration”; pp. 91-103, Shah V. P., M.H.I., Eds. (Plenum: New York, 1993); Frideman, R. M., ‘Interferons: A Primer’, Academic Press, New York, 1981)). Ultrasound has been shown to create cavitation within the SC, which disorders the lipid bilayers and increases drug transport (Walters, In Transdermal Drug Delivery: Developmental Issues and Research Initiatives, Hadraft, ed. (Marcel Dekker, 1989) pp. 197-233).
  • [0006]
    U.S. Pat. No. 4,309,989 to Fahim and U.S. Pat. No. 4,767,402 to Kost, et al., disclose various ways in which ultrasound has been used to achieve transdermal drug delivery. Sonophoresis has been shown to enhance transdermal transport of various drugs. Although a variety of ultrasound conditions have been used for sonophoresis, the most commonly used conditions correspond to the therapeutic ultrasound (frequency in the range of 1 MHz -3 MHz, and intensity in the range of 0-2 W/cm2) (Kost, In Topical Drug Bioavailability Bioequivalence and Penetration, pp. 91-103, Maibach, H. I., Shah, V. P. (Ed) Plenum Press, New York, 1993; U.S. Pat. No. 4,767,402 to Kost, et al.).
  • [0007]
    In spite of these advantages, very few drugs and no proteins or peptides are currently administered transdermally for clinical applications because of the low skin permeability to drugs. Application of therapeutic ultrasound does not induce transdermal transport of high-molecular weight proteins. It is a common observation that the typical enhancement induced by therapeutic ultrasound is less than ten-fold. In many cases, no enhancement of transdermal drug transport has been observed upon ultrasound application. This low permeability is attributed to the stratum comeum (SC), the outermost skin layer which consists of flat, dead cells filled with keratin fibers (keratinocytes) surrounded by lipid bilayers. The highly-ordered structure of the lipid bilayers confers an impermeable character to the SC (Flynn, G. L., In Percutaneous Absorption: Mechanisms—Methodology-Drug Delivery.; Bronaugh, R. L., Maibach, H. I. (Ed), pages 27-53, Marcel Dekker, New York, 1989).
  • [0008]
    A variety of approaches have been suggested to enhance transdermal transport of drugs. These include: i) use of chemicals to either modify the skin structure or to increase the drug concentration in the transdermal patch (Junginger, et al. In “Drug Permeation Enhancement”; Hsieh, D. S., Eds., pp. 59-90 (Marcel Dekker, Inc. New York 1994; Bumette, R. R. In Developmental Issues and Research Initiatives; Hadgraft J., G., R. H., Eds., Marcel Dekker: 1989; pp. 247-288); ii) applications of electric fields to create transient transport pathways [electroporation] (Prausnitz Proc. Natl. Acad. Sci. USA 90, 10504-10508 (1993); Walters, K. A., in Transdermal Drug Delivery: Developmental Issues and Research Initiatives, Ed. Hadgraft J., Guy, R. H., Marcel Dekker, 1989) or to increase the mobility of charged drugs through the skin [iontophoresis], and iii) application of ultrasound [sonophoresis]. Various approaches including chemical enhancers [Walters, K. A., in Transdermal Drug Delivery: Developmental Issues and Research Initiatives, Hadgraft J., Guy, R. H., Marcel Dekker: New York (1989)], ultrasound [Levy et al., J. Clin. Invest., 83: 2074-2078 (1989); Mitragotri et al., J. Pharm. Sci, 84:697-706 (1995)] and electrical enhancement [Prausnitz et al. Proc. Natl. Acad. Sci. USA, 90:10504-10508 (1993); Pliquett et al., Pharmaceutical Research, 12:549-555 (1995); Chizmadzhev et al., Biophysical J. 68:749-765 (1995); Bumette (1989)] have been suggested to enhance transdermal drug transport. In some cases, high strengths of the physico-chemical forces (for example, electricity, ultrasound) are required to deliver a given drug dose transdermally. However, the highest strength of these physico-chemical forces that can be used is limited by their adverse physiological effects.
  • [0009]
    Chemical enhancers have been found to increase transdermal drug transport via several different mechanisms, including increased solubility of the drug in the donor formulation, increased partitioning into the SC, fluidization of the lipid bilayers, and disruption of the intracellular proteins (Kost and Langer, In Topical Drug Bioavailability, Bioequivalence, and Penetration; Shah and Maibech, ed. (Plennum, N.Y. 1993) pp. 91-103 (1993)). U.S. Pat. No. 5,445,611 to Eppstein, et al., describes enhancement of ultrasound using the combination of chemical enhancers with modulation of the frequency, intensity, and/or phase of the ultrasound to induce a type of pumping action. However, the intensity and frequencies used in the examples are quite high, which generates heat and decreasing transport over time.
  • [0010]
    Electroporation is believed to work in part by creating transient pores in the lipid bilayers of the SC (Burnett (1989)). Iontophoresis provides an electrical driving force to move compounds. Electroporation involves application of electric field pulses that create transient aqueous pathways in lipid bilayer membranes, causing a temporary alteration of skin structure. While occurrence of aqueous pores may allow transdermal permeation of neutral molecules by diffusion, the transport of charged molecules during pulsing occurs predominantly by electrophoresis and electroosmosis.
  • [0011]
    Accordingly, a better selection of ultrasound parameters is needed to induce a higher enhancement of transdermal drug transport by sonophoresis. Moreover, although efficacy to some degree has been observed using ultrasound for transport of other compounds, the efficiency of transport under conditions acceptable to patients has not been achieved.
  • [0012]
    It is therefore an object of the present invention to provide a method and means for enhancing transdermal transport.
  • [0013]
    It is a further object of the present invention to provide methods for using ultrasound in combination with other means of enhancement for drug delivery and collection of analyte in an efficient, practical manner.
  • SUMMARY OF THE INVENTION
  • [0014]
    Transdermal transport of molecules during sonophoresis (delivery or extraction) can be further enhanced by the application of an electric field, for example, by iontophoresis or electroporation. In a preferred embodiment, the ultrasound is low frequency ultrasound which induces cavitation of the lipid layers of the stratum corneum (SC). This method i) provides higher transdermal fluxes, ii) allows rapid control of transdermal fluxes, and iii) allows drug delivery or analyte extraction at lower ultrasound intensities than required in the absence of an electric field. Still further enhancement can be obtained using a combination of chemical enhancers and/or magnetic field with the electric field and ultrasound.
  • [0015]
    Examples using two model compounds, calcein and sulphorhodamine, demonstrate that transdermal transport enhancement induced by simultaneous application of ultrasound and electric pulses is higher than that due to electric pulses or ultrasound alone. Application of ultrasound reduces the threshold voltage required for the onset of calcein and sulphorhodamine transport in the presence of electric fields.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0016]
    [0016]FIG. 1A is a graph of sulforhodamine flux/μg/(cm2h) over time (seconds) for electroporation of sulforhodamine, followed by application of electroporation in combination with ultrasound. After 400 sec of passive diffusion, pulsed ultrasound (1 MHz, 20% duty cycle, 2.5-2.9 W/cm2) was turned on for 2750 sec. The ultrasound was turned off at 2750 sec. High voltage pulsing was turned on at 6900 sec for 1 hour (10,500 sec end of electroporation pulsing). Ultrasound (1 MHz, 0.8 cm2 20% duty cycle, 2.5-2.9 W/cm2) was turned on again at 14,310 sec, electroporation was turned on again at 15,200 sec while the pulsed ultrasound was on. At 16,440 sec the ultrasound wave was changed from pulsed to continuous while the electroporation continued.
  • [0017]
    [0017]FIG. 1B is a graph of the time variation of calcein flux in the presence of electric fields alone (X) and during simultaneous application of ultrasound and electric field (0) (1 MHz, 1.4 W/cm2, continuous application, and electric field, 100 V across the skin, exponentially decaying pulse with a time constant (τ) of 1 millisecond, one pulse applied every minute). Ultrasound was ON all the time (O). Electric voltage was turned ON at time 0 and was turned OFF at 1 hour in both the case (O as well as X). Presented as means and S.D. of at least three repetitions.
  • [0018]
    [0018]FIG. 1C. Time variation of sulphorhodamine flux in the presence of electric field alone (X) and during simultaneous application of ultrasound and electric field (O) (1 MHz, 1.4 W/cm2, continuous application, and electric field, 100 V across the skin, exponentially decaying pulse with a time constant (τ) of 1 millisecond, one pulse applied every minute). Ultrasound was ON all the time (O). Electric voltage was turned ON at time O and was turned OFF at 1 hour in both the case (O as well as X). Presented as means and S.D. of at least three repetitions.
  • [0019]
    [0019]FIGS. 2A and 2B are graphs of calcein and sulphorhodamine flux over time (hours), respectively. Skin samples were exposed continuously to electroporation (electric field (750 V across the chamber, equivalent to approximately 210-230 volts across the skin, exponentially decaying pulse with a time constant (τ) of 1 millisecond, one pulse applied every minute) and continuous ultrasound (1 MHz, 0.8 cm2, 2 W/cm2) (o) and controls (x) where the skin was exposed to electric fields alone.
  • [0020]
    [0020]FIG. 3 is a graph of the variation of the transdermal sulphorhodamine flux with the applied electric field (100 V across the skin, exponentially decaying pulse with a time constant (τ) of 1 millisecond, one pulse applied every minute) in the presence (O) and absence (X) of ultrasound. Presented as means and S.D. of at least three repetitions.
  • [0021]
    [0021]FIG. 4. Variation of the normalized transdermal calcein and sulphorhodamine flux under a variety of conditions. A—in the presence of electric field alone, B—in the presence of ultrasound and electric field, C—in the presence of ultrasound alone, D—in the absence of ultrasound and electric field. The transdermal calcein and sulphorhodamine fluxes have been normalized by the corresponding fluxes prior to application of ultrasound, that is, at the end of 0.5 hours. This was done to assist comparison of the relative charges in transdermal flux under different conditions.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0022]
    Sonophoresis:
  • [0023]
    As used herein, sonophoresis is the application of ultrasound to the skin, alone or in combination with chemical enhancers, iontophoresis, electroporation, magnetic force fields, mechanical pressure fields or electrical fields, to facilitate transport of a compound through the skin. In one embodiment, a drug, alone or in combination with a carrier, penetration enhancer, lubricant, or other pharmaceutically acceptable agent for application to the skin, is applied to the skin. In another embodiment, the compound is an analyte such as glucose which is present in a body fluid and extracted by application of the ultrasound, alone or in combination with other forces and/or chemical enhancers.
  • [0024]
    Ultrasound is defined as sound at a frequency of between 20 kHz and 10 MHz, with intensities of between greater than 0 and 3 W/cm2. Ultrasound is preferably administered at frequencies of less than or equal to about 2.5 MHz to induce cavitation of the skin to enhance transport. As used herein, “low frequency” sonophoresis is ultrasound at a frequency that is less than 1 MHz, more typically in the range of 20 to 40 KHz, which can be applied continuously or in pulses, for example, 100 msec pulses every second, at intensities in the range of between zero and 1 W/cm2, more typically between 12.5 mW/cm2 and 225 mW/cm2. Exposures are typically for between 1 and 10 minutes, but may be shorter and/or pulsed. It should be understood that although the normal range of ultrasound begins at 20 kHz, one could achieve comparable results by varying the frequency to slightly more or less than 20 kHz. The intensity should not be so high as to raise the skin temperature more than about one to two degrees Centigrade.
  • [0025]
    Application of low-frequency (20 kHz) ultrasound dramatically enhances transdermal transport of drugs. Transdermal transport enhancement induced by low-frequency ultrasound was found to be as much as 1000-fold higher than that induced by therapeutic ultrasound (frequency in the range of 1 MHz-3 MHz, and intensity in the range of 0-2 W/cm2). Another advantage of low-frequency sonophoresis as compared to therapeutic ultrasound is that the former can induce transdermal transport of drugs which do not passively permeate across the skin. Application of low-frequency ultrasound appears to induce cavitation inside as well as outside the skin. Cavitation occurring at either location may cause disordering of the SC lipids. In addition, oscillations of cavitation bubbles may result in significant water penetration into the disordered lipid regions. -This may cause the formation of aqueous channels through the intercellular lipids of the SC. This allows permeants to transport across the disordered lipid domains, then across keratinocytes and the entire SC. This transport pathway may result in an enhanced transdermal transport as compared to passive transport because the diffusion coefficients of permeants through water, which is likely to primarily occupy the channels generated by ultrasound, are up to 1000-fold higher than those through the ordered lipid bilayers, and the transport path length of these aqueous channels may be much shorter (by a factor of up to 25) than that through the tortuous intercellular lipids in the case of passive transport.
  • [0026]
    Many ultrasound devices are available commercially which can be used in the method described herein. For example, the ultrasonic devices used by dentists to clean teeth have a frequency of between about 25 and 40 KHz. Commercially available portable ultrasound tooth-brushes make use of a small sonicator contained within the tooth-brush (Sonex International Corporation). This sonicator is portable and operates on rechargeable batteries. Small pocket-size sonicators carried by patients and used to “inject” drugs whenever required could be readily adapted from these devices. In addition, these devices could be combined with sensors that can monitor drug concentrations in the blood to formulate a self-controlled drug (insulin, for example) delivery method that can decrease the attention required by the patient.
  • [0027]
    Devices typically used for therapeutic or diagnostic ultrasound operate at a frequency of between 1.6 and 10 MHz. These devices can also be modified for use at lower frequencies. The devices may optionally include a reservoir for an ultrasound gel, which will typically have a sound coefficient like water, or a reservoir for collecting analyte.
  • [0028]
    Although principally described herein as the combination of ultrasound with an electrical field, chemical enhancers and physical enhancers can also be used in combination with ultrasound. Physical enhancers, as used herein, in addition to iontophoresis and electroporation, include magnetic fields and mechanical pressure. Ultrasound is used to permeabilize the skin followed by the application of various force fields to provide additional driving force for transdermal transport of molecules.
  • [0029]
    Electric Fields (Iontophoresis or Electroporation)
  • [0030]
    Application of ultrasound or electric current alone has been shown to enhance transdermal drug transport and blood analyte extraction. As discussed above, ultrasound-induced cavitation occurring inside or outside the skin causes disordering of the SC lipids. Oscillations of cavitation bubbles may also result in significant water penetration into the disordered lipid regions. This may cause the formation of aqueous channels through the intercellular lipids of the SC, thus allowing permeants to transport across the disordered lipid domains. Once able to diffuse across the lipid domains, molecules may diffuse across keratinocytes and hence across the entire SC.
  • [0031]
    Application of electric current enhances transdermal transport by different mechanisms. First, application of an electric field provides an additional driving force for the transport of charged molecules across the skin and second, ionic motion due to application of electric fields may induce convective flows across the skin, referred to as electroosmosis. This mechanism is believed to play a dominant role in transdermal transport of neutral molecules during iontophoresis. Iontophoresis involves the application of an electrical current, preferably DC, or AC, at a current density of greater than zero up to about 1 mA/cm2. Typically, a constant voltage is applied since resistance changes over time, usually in the range of between greater than zero and four volts.
  • [0032]
    Attempts have been made to enhance the skin permeability using electric current to achieve transdermal extraction of glucose, as reported by Tamada, et al., Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 22, 129-130 (1995). Although these attempts have been successful to a certain extent, the amounts of glucose extracted by these methods are several orders of magnitude lower than those which could be detected by the currently existing biosensors. The mechanism of sonophoretic transdermal glucose extraction is believed to be similar to that of sonophoretic transdermal drug delivery. Specifically, application of low-frequency ultrasound increases the skin permeability by disordering its lipid bilayers which leads to the formation of aqueous channels through the intercellular lipids of the SC. This allows faster diffusion of glucose present in the interstitial fluids across the permeabilized skin.
  • [0033]
    The application of ultrasound induces cavitation in the keratinocytes of the stratum corneum. Furthermore, oscillations of cavitation bubbles were shown to induce a partial disorder in the skin lipid bilayer. In view of this, the cumulative effect of ultrasound and electric field may also be related to cavitation induced by ultrasound exposure. In order to test this hypothesis, electric pulses (100 V across the skin, 1 ms exponential pulse applied every minute) and ultrasound (3 MHz, 1.5 W/cm2) were simultaneously applied to skin, as described below. It is known that the cavitational effects vary inversely with ultrasound frequency [Gaertner, W., Frequency dependence of ultrasonic cavitation, J. Acoust. Soc. Am., 26:977-80 (1984)]. No significant cavitational effects have been observed in fluids at high ultrasound frequencies greater than 2.5 MHz. As a result, 2.5 MHz is considered a reasonable estimate of the upper frequency limit for the occurrence of cavitation in fluids at therapeutic ultrasound intensities. Hence, if cavitation plays an important role, the synergistic effect of ultrasound and electric field should be nearly absent when 3 MHz ultrasound is used. Exposure to ultrasound at 3 MHz (intensity =1.5 W/cm2) does not affect transdermal transport by electric field pulsing. These results indicate that cavitation may play a major role in the synergistic effect of ultrasound and electric field pulsing.
  • [0034]
    Chemical Enhancers.
  • [0035]
    Lipid Bilayer Disrupting Agents.
  • [0036]
    Chemical enhancers have been found to increase drug transport by different mechanisms. Chemicals which enhance permeability through lipids are known and commercially available. For example, ethanol has been found to increase the solubility of drugs up to 10,000-fold (Mitragotri, et al. In Encl. of Pharm. Tech.: Swarbrick and Boylan, eds. Marcel Dekker 1995) and yield a 140-fold flux increase of estradiol, while unsaturated fatty acids have been shown to increase the fluidity of lipid bilayers (Bronaugh and Maiback, editors (Marcel Dekker 1989) pp. 1-12).
  • [0037]
    Examples of fatty acids which disrupt lipid bilayer include linoleic acid, capric acid, lauric acid, and neodecanoic acid, which can be in a solvent such as ethanol or propylene glycol. Evaluation of published permeation data utilizing lipid bilayer disrupting agents agrees very well with the observation of a size dependence of permeation enhancement for lipophilic compounds. The permeation enhancement of three bilayer disrupting compounds, capric acid, lauric acid, and neodecanoic acid, in propylene glycol has been reported by Aungst, et al. Pharm. Res. 7, 712-718 (1990). They examined the permeability of four lipophilic compounds, benzoic acid (122 Da), testosterone (288 Da), naloxone (328 Da), and indomethacin (359 Da) through human skin. The permeability enhancement of each enhancer for each drug was calculated according to εc/pg=Pe/pg/Ppg, where Pe/pg is the drug permeability from the enhancer/propylene glycol formulation and Ppg is the permeability from propylene glycol alone.
  • [0038]
    The primary mechanism by which unsaturated fatty acids, such as linoleic acid, are thought to enhance skin permeabilities is by disordering the intercellular lipid domain. For example, detailed structural studies of unsaturated fatty acids, such as oleic acid, have been performed utilizing differential scanning calorimetry (Barry J. Controlled Release 6, 85-97 (1987)) and infrared spectroscopy (Ongpipattanankul, et al., Phann. Res. 8, 350-354 (1991); Mark, et al., J. Control. Rel. 12, 67-75 (1990)). Oleic acid was found to disorder the highly ordered SC lipid bilayers, and to possibly form a separate, oil-like phase in the intercellular domain. SC lipid bilayers disordered by unsaturated fatty acids or other bilayer disrupters may be similar in nature to fluid phase lipid bilayers.
  • [0039]
    A separated oil phase should have properties similar to a bulk oil phase. Much is known about transport in fluid bilayers and bulk oil phases. Specifically, diffusion coefficients in fluid phase, for example, dimyristoylphosphatidylcholine (DMPC) bilayers Clegg and Vaz In “Progress in Protein-Lipid Interactions” Watts, ed. (Elsevier, NY 1985) 173-229; Tocanne, et al., FEB 257, 10-16 (1989) and in bulk oil phase Perry, et al., “Perry's Chemical Engineering Handbook” (McGraw-Hill, NY 1984) are greater than those in the SC, and more importantly, they exhibit size dependencies which are considerably weaker than that of SC transport Kasting, et al., In: “Prodrugs: Topical and Ocular Delivery” Sloan, ed. (Marcel Dekker, NY 1992) 117-161; Potts and Guy, Pharm. Res. 9, 663-339 (1992); Willschut, et al., Chemosphere 30, 1275-1296 (1995). As a result, the diffusion coefficient of a given solute will be greater in a fluid bilayer, such as DMPC, or a bulk oil phase than in the SC. Due to the strong size dependence of SC transport, diffusion in SC lipids is considerably slower for larger compounds, while transport in fluid DMPC bilayers and bulk oil phases is only moderately lower for larger compounds. The difference between the diffusion coefficient in the SC and those in fluid DMPC bilayers or bulk oil phases will be greater for larger solutes, and less for smaller compounds. Therefore, the enhancement ability of a bilayer disordering compound which can transform the SC lipids bilayers into a fluid bilayer phase or add a separate bulk oil phase should exhibit a size dependence, with smaller permeability enhancements for small compounds and larger enhancements for larger compounds.
  • [0040]
    A comprehensive list of lipid bilayer disrupting agents is described in European Patent Application 43,738 (1982), which is incorporated herein by reference. Exemplary of these compounds are those represented by the formula:
  • R—X
  • [0041]
    wherein R is a straight-chain alkyl of about 7 to 16 carbon atoms, a non-terminal alkenyl of about 7 to 22 carbon atoms, or a branched-chain alkyl of from about 13 to 22 carbon atoms, and X is —OH, —COOCH3, —COOC2H, —OCOCH3, —SOCH3, —P(CH3)2O, COOC2H4C2H4OH, —COOCH(CHOH)4CH2O H, —COOCH2CHOHCH3, COOCH2CH(OR″)CH2OR″, —OCH2CH2)mOH, —COOR′, or —CONR′2 where R′ is —H, —CH3, —C2H5, —C2H7 or —C2H4OH; R″ is —H, or a non-terminal alkenyl of about 7 to 22 carbon atoms; and m is 2-6; provided that when R″ is an alkenyl and X is —OH or —COOH, at least one double bond is in the cis-configuration.
  • [0042]
    Solubility Enhancers
  • [0043]
    Suitable solvents include water; diols, such as propylene glycol and glycerol; mono-alcohols, such as ethanol, propanol, and higher alcohols; DMSO; dimethylformamide; N,N-dimethylacetamide; 2-pyrrolidone; N-(2-hydroxyethyl) pyrrolidone, N-methylpyrrolidone, 1-dodecylazacycloheptan-2-one and other n-substituted-alkyl-azacycloalkyl-2-ones and other n-substituted-alkyl-azacycloalkyl-2-ones (azones).
  • [0044]
    U.S. Pat. No. 4,537,776 to Cooper, incorporated herein by reference contains a summary of prior art and-background information detailing the use of certain binary systems for permeant enhancement. European Patent Application 43,738, also describes the use of selected diols as solvents along with a broad category of cell-envelope disordering compounds for delivery of lipophilic pharmacologically-active compounds. A binary system for enhancing metaclopramide penetration is disclosed in UK Patent Application GB 2,153,223 A, consisting of a monovalent alcohol ester of a C8-32 aliphatic monocarboxylic acid (unsaturated and/or branched if C18-32) or a C6-24 aliphatic monoalcohol (unsaturated and/or branched if C14-24) and an N-cyclic compound such as 2-pyrrolidone or N-methylpyrrolidone.
  • [0045]
    Combinations of enhancers consisting of diethylene glycol monoethyl or monomethyl ether with propylene glycol monolaurate and methyl laurate are disclosed in U.S. Pat. No. 4,973,468 for enhancing the transdermal delivery of steroids such as progestogens and estrogens. A dual enhancer consisting of glycerol monolaurate and ethanol for the transdermal delivery of drugs is described in U.S. Pat. No. 4,820,720. U.S. Pat. No. 5,006,342 lists numerous enhancers for transdermal drug administration consisting of fatty acid esters or fatty alcohol ethers of C2 to C4 alkanediols, where each fatty acid/alcohol portion of the ester/ether is of about 8 to 22 carbon atoms. U.S. Pat. No. 4,863,970 discloses penetration-enhancing compositions for topical application including an active permeant contained in a penetration-enhancing vehicle containing specified amounts of one or more cell-envelope disordering compounds such as oleic acid, oleyl alcohol, and glycerol esters of oleic acid; a C2 or C3 alkanol and an inert diluent such as water.
  • [0046]
    Other chemical enhancers, not necessarily associated with binary systems, include dimethylsulfoxide (DMSO) or aqueous solutions of DMSO such as those described in U.S. Pat. No. 3,551,554 to Herschler; U.S. Pat. No. 3,711,602 to Herschler; and U.S. Pat. No. 3,711,606 to Herschler, and the azones (n-substituted-alkyl-azacycloalkyl-2-ones) such as noted in U.S. Pat. No. 4,557,943 to Cooper.
  • [0047]
    Some chemical enhancer systems may possess negative side effects such as toxicity and skin irritations. U.S. Pat. No. 4,855,298 discloses compositions for reducing skin irritation caused by chemical enhancer-containing compositions having skin irritation properties with an amount of glycerin sufficient to provide an anti-irritating effect.
  • [0048]
    Combinations of Lipid Bilayer Disrupting Agents and Solvents
  • [0049]
    Passive experiments without ultrasound with polyethylene glycol 200 dilaurate (PEG), isopropyl myristate (IM), and glycerol trioleate (GT) result in corticosterone flux enhancement values of only 2, 5, and 0.8, relative to the passive flux from PBS alone. However, 50% ethanol and LA/ethanol significantly increase corticosterone passive fluxes by factors of 46 and 900. These passive flux enhancements were due to (1) the increased corticosterone solubility in the enhancers, and (2) interactions of linoleic acid with the skin. Specifically, linoleic acid increased the corticosterone permeability by nearly 20-fold over that from 50% ethanol alone. Therapeutic ultrasound (1 MHz, 1.4 W/cm2) and the chemical enhancers utilized together produce corticosterone fluxes from PBS, PEG, IM, and GT that are greater than the passive fluxes from the same enhancers by factors of between 1.3 and 5.0, indicating that the beneficial effects of chemical enhancers and therapeutic ultrasound can be effectively combined. Ultrasound combined with 50% ethanol produces a 2-fold increase in corticosterone transport above the passive case, but increase by 14-fold the transport from LA/Ethanol. The combination of increased corticosterone solubility in and permeability enhancement from LA/ethanol and ultrasound yields a flux of 0.16 mg/cm2/hr, 13,000-fold greater than that from PBS alone. The permeability enhancement resulting from the addition of linoleic acid to 50% ethanol exhibits a clear size dependence, with the degree of enhancement increasing with the size of the drug. The degree of permeation enhancement achieved by adding linoleic acid to 50% ethanol and applying ultrasound exhibits a similar size dependence. These results suggest that linoleic acid and therapeutic ultrasound, which are both lipid bilayer disordering agents, shift the transport of lipophilic molecules from the passive regime to a regime with a very weak size dependence.
  • [0050]
    Mechanical Forces.
  • [0051]
    Mechanical or Osmotic Pressure
  • [0052]
    The advantages of combining sonophoresis with physical enhancers is not restricted to electrical current. Effects on transdermal transport may also be observed between ultrasound and pressure (mechanical or osmotic) as well as between ultrasound and magnetic fields since the physical principles underlying the enhancement are believed to be similar or the same. A pressure gradient can be used to enhance convection (physical movement of liquid) across the skin permeabilized by sonophoresis. This can be particularly useful in transdermal extraction of blood analytes. Application of pressure, for example, a vacuum or mechanical pressure, to the skin pretreated by sonophoresis can result in transdermal extraction of interstitial fluid which can be analyzed to measure concentration of various blood analytes.
  • [0053]
    Magnetic Fields
  • [0054]
    Application of magnetic fields to the skin pretreated with ultrasound may also result in a higher transport of magnetically active species across the skin. For example, polymer microspheres loaded with magnetic particles could be transported across the skin using sonophoresis and magnetic fields.
  • [0055]
    The combination of sonophoresis with an electric field, and optionally, any of these additional physical mechanisms for enhanced transport provides the following advantages over sonophoresis or the physical enhancers alone: i) It allows lowering application times to deliver a given drug dose or extract a certain amount of analytes compared to the required times in the presence of ultrasound or one.of the other enhancers alone; ii) It reduces the magnitude of the required ultrasound intensity and electric current or pressure to achieve a given transdermal flux compared to that required if, the enhancers were used alone; and iii) It can be used to provide a better control over transdermal transport of molecules compared to that obtained using an enhancer alone.
  • [0056]
    The combination of electrical field and ultrasound can be applied to any membrane. The membrane can be skin, cell membrane, cell wall and other biological as well as synthetic membranes. The electric fields can be continuous, pulsed, having high as well as low voltage. Application of ultrasound together with the electrical fields results in higher flux compared to the flux observed with electroporation or ultrasound alone. The onset time of transdermal flux during electroporation can also be reduced by simultaneous applications of ultrasound and electroporation. The effect is more pronounced on less-charged molecules which by other enhancing methods are hard to enhance (iontophoresis). The major limitation of electroporation are the high voltages required in order to cause significant effect. By using the combined effects of ultrasound and electroporation, the intensity levels of the electrical fields will be much lower and therefore no or less damage to the membranes will be observed.
  • [0057]
    Drug Delivery
  • [0058]
    Drugs to be Administered.
  • [0059]
    Drugs to be administered include a variety of bioactive agents, but are preferably proteins or peptides. Specific examples include insulin, erythropoietin, and interferon. Other materials, including nucleic acid molecules such as antisense and genes encoding therapeutic proteins, synthetic organic and inorganic molecules including antiinflammatories, antivirals, antifungals, antibiotics, local anesthetics, and saccharides, can also be administered.
  • [0060]
    The drug will typically be administered in an appropriate pharmaceutically acceptable carrier having an absorption coefficient similar to water, such as an aqueous gel. Alternatively, a transdermal patch such as the one described in the examples can be used as a carrier. Drug can be administered in a gel, ointment, lotion, suspension or patch, which can incorporate anyone of the foregoing.
  • [0061]
    Drug can also be encapsulated in a delivery device such as a liposome or polymeric nanoparticles, microparticle, microcapsule, or microspheres (referred to collectively as microparticles unless otherwise stated). A number of suitable devices are known, including microparticles made of synthetic polymers such as polyhydroxy acids such as polylactic acid, polyglycolic acid and copolymers thereof, polyorthoesters, polyanhydrides, and polyphosphazenes, and natural polymers such as collagen, polyamino acids, albumin and other proteins, alginate and other polysaccharides, and combinations thereof. The microparticles can have diameters of between 0.001 and 100 microns, although a diameter of less than 10 microns is preferred. The microparticles can be coated or formed of materials enhancing penetration, such as lipophilic materials or hydrophilic molecules, for example, polyalkylene oxide polymers and conjugates, such as polyethylene glycol. Liposome are also commercially available.
  • [0062]
    Administration of Drug.
  • [0063]
    The drug is preferably administered to the skin at a site selected based on convenience to the patient as well as maximum drug penetration. For example, the arm, thigh, or stomach represent areas of relatively thin skin and high surface area, while the hands and feet are uneven and calloused. In the preferred embodiment, drug is applied to the site and ultrasound and electrical current applied immediately thereafter. Other enhancers can be applied before, during or immediately after the ultrasound. Chemical enhancers are preferable administered during or before ultrasound.
  • [0064]
    Based on these calculations and the data in the following examples, one can calculate the required dosage and application regime for treatment of a patient, as follows. A typical diabetic patient (70 Kg weight) takes about 12 Units of insulin three times a day (total dose of about 36 Units per day: cited in ‘World Book of Diabetes in Practice’ Krall, L. P. (Ed), Elsevier, 1988). If each insulin dose was to be delivered by sonophoresis in 1 hour, the required transdermal flux would be 12 U/hour. Note that 1 unit (1 U) of insulin corresponds approximately to 40 mg of insulin. The transdermal patch area used in these calculations is 40 cm2 (the area of a transdermal FENTANYL™ patch [ALZA Corporation]). The donor concentrations used in these calculations are 100 U/ml in the case of insulin (commercially available insulin solution [Humulin]), 3×107 in the case of γ-interferon (typical concentration of interferon solution recommended by Genzyme Corporation), and 3×105 U/ml in the case of erythropoietin [Davis, et al., Biochemistry, 2633-2638, 1987].
  • [0065]
    A typical γ-interferon dose given each time to patients suffering from cancer or viral infections is about 5×106 U [(i) Grups, et al., Br. J. Med., 1989, 64 (3): 218-220, (ii) Parkin, et al., Br. Med. J., 1987, 294: 1185-1186]. Similar doses of α-interferon and β-interferon have also been shown to enhance the immune response of patients suffering from viral infections and cancer (cited in ‘Clinical Applications of interferons and their inducers’, Ed. Stringfellow D., Marcel Dekker, New York, 1986). If this interferon dose was to be given by sonophoresis in 1 hour, the required transdermal flux would be 5×106 U/hour. Note that 1 unit of γ-interferon corresponds approximately to 1 pg of γ-interferon.
  • [0066]
    A typical daily erythropoietin dose given subcutaneously to anemic patients is about 400 U (cited in Subcutaneous Erythropoietin, Bommer J., Ritz E., Weinreich T., Bommer G., Ziegler T., Lancet, 406, 1988). If this dose was to be delivered in three steps, each involving sonophoresis for 1 hour, the transdernal flux required would be about 140 U/hour. Note that 1 unit of erythropoietin corresponds approximately to 7.6 nanograms of erythropoietin.
  • [0067]
    Optimal selection of ultrasound parameters, such as frequency, pulse length, intensity, as well as of non-ultrasonic parameters, such as ultrasound coupling medium, can be conducted to ensure a safe and efficacious application using the guidelines disclosed herein as applied by one of ordinary skill in the art.
  • [0068]
    Measurement of Analytes
  • [0069]
    Analytes to be Measured.
  • [0070]
    A variety of analytes are routinely measured in the blood, lymph or other body fluids. Measurements usually require making a puncture in order to withdraw sample. Examples of typical analytes that can be measured include blood sugar (glucose), cholesterol, bilirubin, creatine, various metabolic enzymes, hemoglobin, heparin, vitamin K or other clotting factors, uric acid, carcinoembryonic antigen or other tumor antigens, and various reproductive hormones such as those associated with ovulation or pregnancy. Transdermal drug delivery, in combination with the non-invasive blood analyte measurements, may be used to formulate self-regulated drug delivery methods which provide a close control of the blood concentrations, minimal pain, and better patient compliance. Non-invasive blood analysis method includes extraction of various analytes from the skin's interstitial fluids (where the analytes are present at a concentration proportional to the blood concentration) across the skin into a patch, solution or gel, where their concentration can be measured using biosensors. This method of blood analyte measurements should be particularly useful in the case of diabetic patients who require multiple daily blood glucose measurements.
  • [0071]
    Measurement of Analytes.
  • [0072]
    The ultrasound is applied to the skin at the site where the sample is to be collected. A reservoir or collecting container is applied to the site for collection of the sample, which is then measured using standard techniques. The ultrasound conditions are optimized as in the case for drug delivery, to maximize analyte recovery, while maintaining the relative levels of the analyte to other components of the sample. Chemical and/or physical enhancers are applied to the site before, during and after the ultrasound, preferably during or before the ultrasound.
  • [0073]
    The present invention will be further understood by reference to the following non-limiting examples.
  • EXAMPLE 1
  • [0074]
    Comparison of Drug Transfer Through Skin using Ultrasound or Electrical Field Alone or in Combination.
  • [0075]
    Material and Methods
  • [0076]
    A. Materials
  • [0077]
    Full thickness of human cadaver skin (obtained from local hospitals) was heat stripped by immersion in 60° C. water for two minutes followed by the removal of the epidermis. The skin was then stored in a humidified chamber (95% relative humidity) at 4° C. The heat-stripped human epidermis was placed in a custom-made side-by-side permeation chamber, skin area of 0.64 cm2, designed to adapt an ultrasound transducer at the donor side. The donor compartment was filled with a 1 mM solution of calcein (MW 623, electric charge -4; Sigma Chemicals) (CA) and 1 mM sulphorhodamine (MW 607, electric charge -1; Sigma Chemical) (SR) in 150 mM Phosphate Buffer Saline (PBS; Sigma Chemicals).
  • [0078]
    The ultrasound probe was inserted into the donor compartment. The direction of the ultrasound wave was perpendicular to the membrane surface. The stratum comeum was facing the donor compartment. Both donor and receptor compartments were filled with degassed phosphate buffer saline (PBS) pH=7.4. The temperature was followed to be in the range of 22±2° C. SR and CA were added to the donor compartment to provide concentration of 1 mM CA and 1 mM SR. Fresh PBS was continuously pumped into the receptor compartment at 0.8 ml/min from a reservoir.
  • [0079]
    B. Fluorescence measurements
  • [0080]
    The fluorometer was set up for dual wavelength measurements (excitation wavelength=488 nm, emission wavelength=515 nm (calcein), and excitation wavelength=586 nm, emission wavelength=607 nm (sulphorhodamine)). The sample cuvette of the fluorometer was sealed but for two openings that were provided for the flow of receiver fluid through it. A small custom-made electric stirrer was installed in the cuvette so that there were no stagnant zones in it. Care was taken to avoid any obstruction of the excitation beam by the stirrer. Transdermal calcein and sulphorhodamine flux was calculated from the fluorescence readings by taking into account parameters such as flow rate, receiver compartment volume, and fluorometer caveat volume. The effluent from the receptor compartment was pumped through a spectrofluorometer (Fluorolog-II-system F112AI SPEX-industries, Edison, N.J.) where the fluorescence of calcein and sulphorhodamine was separately measured twice every minute. The excitation for CA is 488 nm and for SR 586 nm, the measurement for CA was at 515 mn and for SR 607 nm. The receptor was mixed by an electromechanical stirrer. The fluorescence measurements were deconvoluted to calculate the CA and SR flux.
  • [0081]
    C. Application of Ultrasound
  • [0082]
    Two studies were conducted. In the first, two ultrasound sources were utilized:
  • [0083]
    i. 20 KHz Sonics and Materials (250 W) with a probe surface area of 0.25 cm2.
  • [0084]
    ii. 1 MHz Sonopuls Therapeutic device with probe surface area of 0.8 cm2. Pulsed and continuous modes were evaluated below 2 W/cm2 for the continuous mode and 2-3 W/cm2 pulsed (20% duty-cycle). The distance of the probe tips from the skin was 3 cm for the 20 KHz and 4 cm for the 1 MHz.
  • [0085]
    In the second study, ultrasound was applied under therapeutically approved conditions (1.4 W/cm2, 1 MHz and 3 MHz, continuous) using a sonicator (Sonopuls 463, Henley International) for various exposure times up to 1 hour. The ultrasound transducer was located at a distance of about 3 cm from the skin.
  • [0086]
    D. Electroporation
  • [0087]
    One Ag/AgCl electrode (In vivo metric, Healdsburg, Calif.) was located in the donor and one in the receptor compartment, so that the distance of electrodes from the skin was equal in both the compartments (about 8 mm). Voltage pulses were applied using a pulse generator (ECM 600, BTX, San Diego, Calif.) across the electrodes such that the positive electrode was always in the receptor compartment. This provided an electric driving force for calcein and sulphorhodamine (both negatively charged) to transport across the skin. The voltage applied to the electrodes divides between the saline and the skin. The voltage drop across the skin was estimated using the measured electrical resistance of the skin and saline. The magnitude as well as the length of the voltage pulses was varied over a wide range in order to investigate their effect on transdermal transport.
  • [0088]
    In the first set of experiments (FIGS. 1A, 1B, 2A), a voltage divider of 10:40 ohm was used to provide a fixed time constant (exponential shape pulse). The maximum pulsing voltage in all experiments was 750 volts across the chamber (refers to a voltage drop across the skin of 210-230 volts). The pulse rate was 1 pulse/min for 60 minutes, controlled by a computer.
  • [0089]
    In the second set of studies (FIGS. 1C, 2B and 2C, 3), the electric field (100 V) was applied across the skin, exponentially decaying pulse with a time constant (T) of 1 millisecond, one pulse applied every minute.
  • [0090]
    In order to assess the stability of these molecules during electroporation, calcein and sulphorhodamine solutions (1 mM each) were exposed to electroporating conditions similar to those used in this study. No difference between the intensity of their fluorescence before and after exposure to electric fields could be detected. In addition, these molecules are stable up to a temperature of 100° C. (measured in terms of fluorescence). When these molecules are degraded, they do not fluoresce. In general, these molecules have been found to be very stable against many physico-chemical changes.
  • [0091]
    E. Measurements of Passive Electric Skin Properties
  • [0092]
    A second pair of electrodes (same type as above) was used for monitoring the passive electrical properties (specifically, electrical resistance). Since the electrical resistance of the skin is a good indicator of its barrier properties, the skin resistance was measured before, during and after the experiments. The effect of electroporation and ultrasound separately and together on skin electrical resistance was determined. If the electrical resistivity before the application of either ultrasound or electroporation was lower than 20 kΩ-cm2 or if any significant passive calcein or sulphorhodamine transdermal flux was observed (that is, J greater than 0.002 μg/cm2/h (the detection limit)), the skin piece was considered leaky and replaced by a new piece.
  • [0093]
    Results and Discussion
  • [0094]
    A. Application of Ultrasound Enhances the Efficacy of Electric Field.
  • [0095]
    The results of the first study are shown in FIG. 1A. FIG. 1A shows the time variation flux of SR which permeated the skin with time. After 400 sec of passive diffusion, pulsed ultrasound (1 MHz, 20% duty cycle, 2.5-2.9 W/cm2) was turned on for 2750 sec. The ultrasound was turned off at 2750 sec. High voltage pulsing was turned on at 6900 sec for 1 hour (10,500 sec end of electroporation pulsing). Ultrasound (1 MHz, 0.8 cm2 20% duty cycle, 2.5-2.9 W/cm2) was turned on again at 14,310 sec, electroporation (same condition) was turned on again at 15,200 sec while the pulsed ultrasound was on. At 16,440 sec the ultrasound wave was changed from pulsed to continuous while the electroporation continued. The experiment was terminated at 20,040 sec. The experimental procedure is summarized in table 1 below.
    TABLE 1
    Conditions used for determining effect of ultrasound and electroporation
    Description of the
    From (sec) To (sec) transdermal transport
      0  400 passive diffusion
     400  3150 pulsed ultrasound
     3150  6900 passive diffusion
     6900 10500 electroporation
    10500 14310 passive diffusion
    14310- 15200 pulsed ultrasound
    15200- 16400 electroporation +
    pulsed ultrasound
    16440- 20040 electroporation +
    continuous ultrasound
  • [0096]
    [0096]FIGS. 1B and 1C show the effect of simultaneous application of ultrasound (1 MHz, 1.4 W/cm2, continuous application) and electric field (100 V across the skin, exponentially decaying pulse with a time constant (τ) of 1 millisecond, one pulse applied every minute) on the transdermal transport of calcein and sulphorhodamine respectively. The passive transdermal transport (in the absence of ultrasound and electric field) is below the detection limit and is not shown in FIG. 1B or 1C. Application of ultrasound alone does not enhance the flux of calcein or sulphorhodamine. However, application of ultrasound enhanced steady-state transdermal flux of both calcein and sulphorhodamine during electric field pulsing. The enhancement is quantitatively defined as the amount of calcein or sulphorhodamine transported in the presence of ultrasound-electric field pulsing to that in the presence of electric field pulsing alone. This ratio is 2 in the case of calcein (FIG. 1B), and 3 in the case of sulphorhodamine (FIG. 1C). Application of ultrasound also reduced transdermal calcein transport lag time, defined as the time required to reach the steady state, from a typical value of 15 minutes in the presence of electric field alone to about 9 minutes in the presence of ultrasound and electric field.
  • [0097]
    Similar effects of ultrasound on transdermal transport of SR and CA during electroporation can be also seen in FIGS. 2A and 2B which present the flux of CA (FIG. 2A) and SR (FIG. 2B) in experiments where the skin samples were exposed continuously to electroporation and continuous ultrasound (1 MHz, 0.8 cm2, 2 W/cm2) (o) and controls (x) where the skin was exposed to electric fields alone. The possible mechanism for this phenomena might be that the electrical pulsing creates short term pores in the skin while ultrasound is forcing the solutes through these pores.
  • [0098]
    In order to quantitatively estimate the reduction in the required pulsing voltages by simultaneous application of ultrasound and electric field, transdermal sulphorhodamine transport was measured in the presence as well as absence of ultrasound (1 MHz, 1.4 W/cm2) and electric field (voltage across the skin increased from 20 V to 150 V in steps of 5 V every 30 minutes, 1 millisecond exponential pulse applied every minute).
  • [0099]
    [0099]FIG. 3 shows the variation of transdermal sulphorhodamine flux with voltage across the skin in the presence (O) as well as in the absence (X) of ultrasound. The transdermal sulphorhodamine flux is nearly zero as long as the voltage is below the threshold value and thereafter increases linearly with voltage. The threshold voltage for this pulsing protocol can be estimated by measuring the intercept of the linear variation of flux with voltage on the voltage axis. In the absence of ultrasound, this threshold is about 53±3 V and that in the presence of ultrasound is about 46±3 V, indicating that application of ultrasound slightly reduces the threshold pulsing voltage. FIG. 3 also shows that the transdermal sulphorhodamine flux at various pulsing voltages is always higher in the presence of ultrasound. Thus, the pulsing voltage required to achieve a given transdermal flux is smaller in the presence of ultrasound. For example, to achieve a transdermal sulphorhodamine flux of 0.15 μg/cm2/hr, the required voltage is about 95 V in the absence of ultrasound and 75 V in the presence of ultrasound.
  • [0100]
    Cavitation may play a two-fold role in enhancing the effect of electric field on transdermal transport. First, oscillations of cavitation bubbles induce partial structural disordering of the skin's lipid bilayers. Since the electrical resistance of the disordered bilayers is likely to be smaller than that of the normal lipid bilayers, the applied electric field may concentrate preferentially across the normal bilayers. This may decrease the threshold electroporating voltage for transdermal transport of calcein and sulphorhodamine. Application of ultrasound reduces the threshold pulsing voltage from about 53±3 V in the absence of ultrasound to about 46±3 V in the presence of ultrasound (a reduction of about 12%). This number is comparable to an independent estimate of the fraction of SC bilayer disordered by ultrasound application (15%).
  • [0101]
    The oscillations of cavitation bubbles may also induce convection across the skin. In order to assess the role of convection in the synergistic effect of ultrasound and electric field, transdermal calcein and sulphorhodamine transport was measured sequentially in the presence of electric field alone, ultrasound and electric field, ultrasound alone and in the absence of ultrasound and electric field. The results of these sequential procedure are shown in FIG. 4. Results from a single experiment are shown to depict the shape of the curves clearly. Note the change in the transdermal flux at 1 and 1.5 hours when electric field and ultrasound is turned OFF respectively. If electrophoresis plays an important role in calcein and sulphorhodamine transport, the transdermal flux is likely to decrease rapidly after electric fields is turned OFF. On the other hand, if cavitation-induced convection plays an important role, transdermal flux would rapidly decrease after turning ultrasound OFF. Indeed, calcein flux decreases rapidly after turning electric field OFF (1 hour) and achieves a value comparable to the background flux. When ultrasound is turned OFF at 1.5 hours, calcein flux further decreases by a small amount (compared to the reduction after turning electric field OFF at 1 hour) and thereafter it remains nearly at the background level. This suggests that calcein transport is mainly driven by electric forces. On the other hand, convection appears to play an important role in transdermal sulphorhodamine transport in the presence of ultrasound and electric field because the sulphorhodamine flux did not decrease rapidly after turning electric fields OFF, but decreased instantaneously after turning ultrasound OFF at 1.5 hours. The total decrease in the transdermal sulphorhodamine flux after turning the electric field OFF (that is, between a period of 1 and 1.5 hours) is comparable to the instantaneous decrease in its value after turning ultrasound OFF at 1.5 hours. This suggests that both electric field and ultrasound-generated convection may play an important role in transdermal sulphorhodamine transport. This difference in the behavior of calcein and sulphorhodamine is presumably because calcein possesses a much larger charge (4) compared to sulphorhodamine (−1). In this respect, it is important to note that the transdermal transport of calcein and sulphorhodamine in the presence of electric field alone also differs significantly. Calcein transport increases rapidly and achieves a steady state within 15 minutes. Sulphorhodamine flux, however, increases continuously with time over the experimental duration. This difference in the behavior of calcein and sulphorhodamine flux may also be attributed to the lower charge on sulphorhodamine, as the transport during the electrical pulses is driven by electrophoresis.
  • [0102]
    The combined effect of electroporation and ultrasound on transdermal flux in all experiments was higher for SR than CA, suggesting that the additional enhancement by ultrasound is more effective on less charged molecules. The effect of ultrasound was observed on both the lag time and the steady state flux for the two molecules.
  • [0103]
    In summary, electroporation of the skin resulted in a very significant increase in SR permeability. The phenomenon was observed also on repeated application of electroporation, but the enhancing effect was only slightly higher. Application of ultrasound without electroporation did not result in enhanced flux. The very pronounced increase in permeability was observed when the skin was exposed to the combined effect of ultrasound and electroporation (more than twice the flux value observed with electroporation without ultrasound). The combined effect of ultrasound and electroporation was also observed in additional exposures of the same skin specimens.
  • EXAMPLE 2
  • [0104]
    Determination of Effect of Ultrasound on Skin.
  • [0105]
    The following experiment was measured in order to assess whether application of ultrasound induces any irreversible change in the skin structure. Human skin pieces were exposed to electric field alone (100 V across the skin, exponentially decaying pulse with a time constant (τ) of 1 millisecond, one pulse applied every minute), then simultaneously to ultrasound (1 MHz, 1.4 W/cm2)-electric field and again to electric field alone. A comparison of sulphorhodamine transport due to the electric field alone, before and after the simultaneous electric field-ultrasound treatment, indicated that the flux returns to a near baseline value, suggesting that the application of ultrasound did not induce any irreversible alteration in the barrier properties of skin. The recovery was also supported by electric resistance measurements indicating that application of ultrasound did not cause any irreversible change in the electrical resistance of the skin.
  • [0106]
    Modifications and variations of the present invention will be obvious to those skilled in the art from the foregoing detailed description, and are intended to come within the scope of the appended claims.

Claims (12)

    We claim:
  1. 1. A method for enhancing transdermal transport of compounds comprising administering to the skin an effective amount of ultrasound in combination with an electric field.
  2. 2. The method of
    claim 1
    wherein the ultrasound is administered at a frequency of less than 2.5 MHz.
  3. 3. The method of
    claim 1
    wherein the ultrasound is administered at a frequency of 1 MHz or less.
  4. 4. The method of
    claim 1
    wherein the intensity of the ultrasound is less than 2.5 W/cm2.
  5. 5. The method of
    claim 1
    wherein the intensity of the ultrasound is less than 1.5 W/cm2.
  6. 6. The method of
    claim 1
    wherein the ultrasound is administered with agents enhancing solubility of the compounds to be transported in combination with agents enhancing the fluidity of lipid bilayers.
  7. 7. The method of
    claim 1
    wherein the ultrasound is administered in combination with an electric force field selected from the group consisting of electroporation and iontophoresis.
  8. 8. The method of
    claim 1
    wherein the compound to be transported is a drug the patient is in need of.
  9. 9. The method of
    claim 1
    wherein the compound to be transported is an analyte to be measured.
  10. 10. The method of
    claim 1
    wherein the electric field is pulsed.
  11. 11. The method of
    claim 1
    wherein the ultrasound is pulsed.
  12. 12. An apparatus for applying ultrasound and an electric field to skin in an amount effect to enhance transport of molecules through the skin without damaging the skin.
US09528506 1995-12-18 2000-03-20 Effect of electric field and ultrasound for transdermal drug delivery Abandoned US20010056255A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US08574377 US5947921A (en) 1995-12-18 1995-12-18 Chemical and physical enhancers and ultrasound for transdermal drug delivery
US08626021 US6041253A (en) 1995-12-18 1996-04-01 Effect of electric field and ultrasound for transdermal drug delivery
US09528506 US20010056255A1 (en) 1995-12-18 2000-03-20 Effect of electric field and ultrasound for transdermal drug delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09528506 US20010056255A1 (en) 1995-12-18 2000-03-20 Effect of electric field and ultrasound for transdermal drug delivery
US10839571 US20040210184A1 (en) 1995-12-18 2004-05-05 Effect of electric field and ultrasound for transdermal drug delivery

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08626021 Continuation US6041253A (en) 1995-12-18 1996-04-01 Effect of electric field and ultrasound for transdermal drug delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10839571 Continuation US20040210184A1 (en) 1995-12-18 2004-05-05 Effect of electric field and ultrasound for transdermal drug delivery

Publications (1)

Publication Number Publication Date
US20010056255A1 true true US20010056255A1 (en) 2001-12-27

Family

ID=27076376

Family Applications (3)

Application Number Title Priority Date Filing Date
US08626021 Expired - Fee Related US6041253A (en) 1995-12-18 1996-04-01 Effect of electric field and ultrasound for transdermal drug delivery
US09528506 Abandoned US20010056255A1 (en) 1995-12-18 2000-03-20 Effect of electric field and ultrasound for transdermal drug delivery
US10839571 Abandoned US20040210184A1 (en) 1995-12-18 2004-05-05 Effect of electric field and ultrasound for transdermal drug delivery

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08626021 Expired - Fee Related US6041253A (en) 1995-12-18 1996-04-01 Effect of electric field and ultrasound for transdermal drug delivery

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10839571 Abandoned US20040210184A1 (en) 1995-12-18 2004-05-05 Effect of electric field and ultrasound for transdermal drug delivery

Country Status (1)

Country Link
US (3) US6041253A (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040062780A1 (en) * 2002-10-01 2004-04-01 Keller Brian C. Compositions and methods useful for the reduction of fine lines and wrinkles
US20040087007A1 (en) * 2000-07-14 2004-05-06 Transform Pharmaceuticals, Inc. System and method for optimizing tissue barrier transfer of compounds
US20040142460A1 (en) * 2002-10-28 2004-07-22 Michael Cima Raised surface assay plate
US20040235145A1 (en) * 2000-07-14 2004-11-25 Cima Michael J. Transdermal assay with magnetic clamp
US20050208477A1 (en) * 2002-10-28 2005-09-22 Transform Pharmaceuticals, Inc. Raised surface assay plate
EP1706176A2 (en) * 2004-01-09 2006-10-04 Alza Corporation Frequency assisted transdermal agent delivery method and system
US7172859B2 (en) 2000-07-14 2007-02-06 Transform Pharmaceuticals, Inc. System and method for optimizing tissue barrier transfer of compounds
US7537590B2 (en) 2004-07-30 2009-05-26 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
US7679407B2 (en) 2003-04-28 2010-03-16 Abbott Diabetes Care Inc. Method and apparatus for providing peak detection circuitry for data communication systems
US7756561B2 (en) 2005-09-30 2010-07-13 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US7768408B2 (en) 2005-05-17 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
US7922458B2 (en) 2002-10-09 2011-04-12 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
US8029460B2 (en) 2005-03-21 2011-10-04 Abbott Diabetes Care Inc. Method and system for providing integrated medication infusion and analyte monitoring system
US8047811B2 (en) 2002-10-09 2011-11-01 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
US8112138B2 (en) 2005-06-03 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US8343093B2 (en) 2002-10-09 2013-01-01 Abbott Diabetes Care Inc. Fluid delivery device with autocalibration
US8344966B2 (en) 2006-01-31 2013-01-01 Abbott Diabetes Care Inc. Method and system for providing a fault tolerant display unit in an electronic device
US8403915B2 (en) 2004-09-01 2013-03-26 Microchips, Inc. Multi-opening reservoir devices for controlled release or exposure of reservoir contents
US8467972B2 (en) 2009-04-28 2013-06-18 Abbott Diabetes Care Inc. Closed loop blood glucose control algorithm analysis
US8560082B2 (en) 2009-01-30 2013-10-15 Abbott Diabetes Care Inc. Computerized determination of insulin pump therapy parameters using real time and retrospective data processing
US8579853B2 (en) 2006-10-31 2013-11-12 Abbott Diabetes Care Inc. Infusion devices and methods
US8638220B2 (en) 2005-10-31 2014-01-28 Abbott Diabetes Care Inc. Method and apparatus for providing data communication in data monitoring and management systems
US8798934B2 (en) 2009-07-23 2014-08-05 Abbott Diabetes Care Inc. Real time management of data relating to physiological control of glucose levels
WO2016004442A3 (en) * 2014-07-03 2016-03-31 Redding Bruce K Jr Method and apparatus for measuring the dose remaining upon a transdermal drug delivery device

Families Citing this family (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956032B1 (en) * 1986-04-18 2005-10-18 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
US6385487B1 (en) 1996-05-08 2002-05-07 Biophoretic Therapeutic Systems, Llc Methods for electrokinetic delivery of medicaments
USRE37796E1 (en) 1997-12-16 2002-07-23 Biophoretic Therapeutic Systems, Llc Methods for iontophoretic delivery of antiviral agents
US5676648A (en) 1996-05-08 1997-10-14 The Aps Organization, Llp Iontophoretic drug delivery apparatus and method for use
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US20040204669A1 (en) * 2001-07-05 2004-10-14 Hofmann Gunter A. Apparatus for electroporation mediated delivery for drugs and genes
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US8287483B2 (en) 1998-01-08 2012-10-16 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
US20060015058A1 (en) * 1998-01-08 2006-01-19 Kellogg Scott C Agents and methods for enhancement of transdermal transport
US7066884B2 (en) * 1998-01-08 2006-06-27 Sontra Medical, Inc. System, method, and device for non-invasive body fluid sampling and analysis
US20020055702A1 (en) * 1998-02-10 2002-05-09 Anthony Atala Ultrasound-mediated drug delivery
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20040229363A1 (en) * 1998-06-24 2004-11-18 Ed Nolan High efficiency transfection based on low electric field strength, long pulse length
JP2002519641A (en) 1998-06-24 2002-07-02 トランスダーム ダイアグノスティックス, インコーポレイテッド Non-invasive transdermal detection of analytes
US7922709B2 (en) 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US6678556B1 (en) * 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
JP2003505114A (en) * 1998-07-13 2003-02-12 ジェネトロニクス、インコーポレーテッド Gene therapy of skin and muscle by pulsed electric field targeted
US6148231A (en) * 1998-09-15 2000-11-14 Biophoretic Therapeutic Systems, Llc Iontophoretic drug delivery electrodes and method
DE19850517B4 (en) * 1998-11-03 2004-02-12 Lts Lohmann Therapie-Systeme Ag Use of a drug-containing transdermal therapeutic system in a combination treatment with and without ultrasound
US6708060B1 (en) * 1998-11-09 2004-03-16 Transpharma Ltd. Handheld apparatus and method for transdermal drug delivery and analyte extraction
US6597946B2 (en) * 1998-11-09 2003-07-22 Transpharma Ltd. Electronic card for transdermal drug delivery and analyte extraction
US6611706B2 (en) 1998-11-09 2003-08-26 Transpharma Ltd. Monopolar and bipolar current application for transdermal drug delivery and analyte extraction
US6148232A (en) 1998-11-09 2000-11-14 Elecsys Ltd. Transdermal drug delivery and analyte extraction
US20040171980A1 (en) 1998-12-18 2004-09-02 Sontra Medical, Inc. Method and apparatus for enhancement of transdermal transport
US6317630B1 (en) * 1999-01-29 2001-11-13 Yossi Gross Drug delivery device
US6792306B2 (en) * 2000-03-10 2004-09-14 Biophoretic Therapeutic Systems, Llc Finger-mounted electrokinetic delivery system for self-administration of medicaments and methods therefor
US7127285B2 (en) * 1999-03-12 2006-10-24 Transport Pharmaceuticals Inc. Systems and methods for electrokinetic delivery of a substance
US6627421B1 (en) * 1999-04-13 2003-09-30 Imarx Therapeutics, Inc. Methods and systems for applying multi-mode energy to biological samples
GB0002856D0 (en) * 2000-02-08 2000-03-29 Gendel Limited Ultrasound sensitisation
JP2004504073A (en) 2000-02-18 2004-02-12 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション Method for delivering a drug with an alternating current
US7137975B2 (en) * 2001-02-13 2006-11-21 Aciont, Inc. Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent
WO2001060448A1 (en) 2000-02-18 2001-08-23 University Of Utah Research Foundation Methods for extracting substances using alternating current
WO2001087193A1 (en) * 2000-05-16 2001-11-22 Rensselaer Polytechnic Institute Electrically conducting nanocomposite materials for biomedical applications
US6477410B1 (en) 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
US6540675B2 (en) * 2000-06-27 2003-04-01 Rosedale Medical, Inc. Analyte monitor
US20080182293A1 (en) * 2000-07-14 2008-07-31 Transform Pharmaceuticals, Inc. Computerized control of high-throughput transdermal experimental processing and digital analysis of comparative samples
US6908448B2 (en) * 2001-08-24 2005-06-21 Dermisonics, Inc. Substance delivery device
US20020156415A1 (en) * 2000-08-24 2002-10-24 Redding Bruce K. Ultrasonically enhanced substance delivery system and device
US20050075598A1 (en) * 2001-08-24 2005-04-07 Redding Bruce K. Method and apparatus for the measurement of real time drug delivery through the use of a wearable monitor and sensor attached to a transdermal drug delivery device
US20040138412A1 (en) * 2001-09-07 2004-07-15 Paolo Botti Extended native chemical ligation
DE60144188D1 (en) * 2000-09-08 2011-04-21 Amylin Pharmaceuticals Inc "pseudo"-native chemische ligation
US6964647B1 (en) * 2000-10-06 2005-11-15 Ellaz Babaev Nozzle for ultrasound wound treatment
US6882884B1 (en) * 2000-10-13 2005-04-19 Soundskin, L.L.C. Process for the stimulation of production of extracellular dermal proteins in human tissue
US6487447B1 (en) * 2000-10-17 2002-11-26 Ultra-Sonic Technologies, L.L.C. Method and apparatus for in-vivo transdermal and/or intradermal delivery of drugs by sonoporation
US6601581B1 (en) 2000-11-01 2003-08-05 Advanced Medical Applications, Inc. Method and device for ultrasound drug delivery
US20050043726A1 (en) * 2001-03-07 2005-02-24 Mchale Anthony Patrick Device II
US6821274B2 (en) * 2001-03-07 2004-11-23 Gendel Ltd. Ultrasound therapy for selective cell ablation
EP1353723A2 (en) * 2000-11-17 2003-10-22 Gendel Limited Ablation of cells using combined electric field and ultrasound therapy
US7481781B2 (en) * 2000-11-17 2009-01-27 Gendel Limited Ultrasound therapy
DE10057832C1 (en) 2000-11-21 2002-02-21 Hartmann Paul Ag Blood analysis device has syringe mounted in casing, annular mounting carrying needles mounted behind test strip and being swiveled so that needle can be pushed through strip and aperture in casing to take blood sample
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US6533803B2 (en) 2000-12-22 2003-03-18 Advanced Medical Applications, Inc. Wound treatment method and device with combination of ultrasound and laser energy
US6761729B2 (en) 2000-12-22 2004-07-13 Advanced Medicalapplications, Inc. Wound treatment method and device with combination of ultrasound and laser energy
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US8235919B2 (en) * 2001-01-12 2012-08-07 Celleration, Inc. Ultrasonic method and device for wound treatment
US6569099B1 (en) 2001-01-12 2003-05-27 Eilaz Babaev Ultrasonic method and device for wound treatment
US7914470B2 (en) * 2001-01-12 2011-03-29 Celleration, Inc. Ultrasonic method and device for wound treatment
US6960173B2 (en) * 2001-01-30 2005-11-01 Eilaz Babaev Ultrasound wound treatment method and device using standing waves
WO2002068676A3 (en) * 2001-02-27 2003-12-24 Harold C Smith METHODS AND COMPOSITIONS FOR MODIFYING APOLIPOPROTEIN B mRNA EDITING
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US6623444B2 (en) 2001-03-21 2003-09-23 Advanced Medical Applications, Inc. Ultrasonic catheter drug delivery method and device
WO2002078512A8 (en) 2001-04-02 2004-12-02 Therasense Inc Blood glucose tracking apparatus and methods
US6980854B2 (en) * 2001-04-06 2005-12-27 Mattioli Engineering Ltd. Method and apparatus for skin absorption enhancement and transdermal drug delivery of lidocaine and/or other drugs
US7496401B2 (en) * 2001-04-06 2009-02-24 Mattioli Engineering Ltd Method and apparatus for skin absorption enhancement and transdermal drug delivery
KR100783195B1 (en) * 2001-04-06 2007-12-06 마티올리 엔지니어링 엘티디. Apparatus for skin absorption enhancement
US7010343B2 (en) 2001-04-06 2006-03-07 Mattioli Engineering Ltd. Method and apparatus for skin absorption enhancement and transdermal drug delivery
US7520875B2 (en) * 2001-04-06 2009-04-21 Mattioli Engineering Ltd. Method and apparatus for skin absorption enhancement and transdermal drug delivery
US7083580B2 (en) * 2001-04-06 2006-08-01 Mattioli Engineering Ltd. Method and apparatus for skin absorption enhancement and transdermal drug delivery
US6478754B1 (en) 2001-04-23 2002-11-12 Advanced Medical Applications, Inc. Ultrasonic method and device for wound treatment
US6503209B2 (en) 2001-05-18 2003-01-07 Said I. Hakky Non-invasive focused energy blood withdrawal and analysis system
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
EP1404235A4 (en) 2001-06-12 2008-08-20 Pelikan Technologies Inc Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7297122B2 (en) 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7316700B2 (en) 2001-06-12 2008-01-08 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US7682318B2 (en) 2001-06-12 2010-03-23 Pelikan Technologies, Inc. Blood sampling apparatus and method
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7371247B2 (en) 2002-04-19 2008-05-13 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7699791B2 (en) 2001-06-12 2010-04-20 Pelikan Technologies, Inc. Method and apparatus for improving success rate of blood yield from a fingerstick
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US7481776B2 (en) 2002-04-19 2009-01-27 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
WO2002100460A3 (en) 2001-06-12 2003-05-08 Don Alden Electric lancet actuator
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7291117B2 (en) 2002-04-19 2007-11-06 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7344507B2 (en) 2002-04-19 2008-03-18 Pelikan Technologies, Inc. Method and apparatus for lancet actuation
US7491178B2 (en) 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US6823212B2 (en) 2001-06-13 2004-11-23 The Procter & Gamble Company Method and apparatus for measuring properties of a target surface
US7008650B2 (en) * 2001-08-09 2006-03-07 Lam Paul Y S Compositions for the treatment of acquired immunodeficiency disease
JP3816809B2 (en) * 2002-01-30 2006-08-30 株式会社日立製作所 Drugs, drug carriers, a method of treatment of drug preparation and tumors
US7004928B2 (en) 2002-02-08 2006-02-28 Rosedale Medical, Inc. Autonomous, ambulatory analyte monitor or drug delivery device
US7218962B2 (en) * 2002-03-29 2007-05-15 Boston Scientific Scimed, Inc. Magnetically enhanced injection catheter
EP1499255B1 (en) * 2002-04-19 2015-07-22 Syneron Medical Ltd. Handheld transdermal drug delivery and analyte extraction
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
JP4243499B2 (en) * 2002-06-11 2009-03-25 富士通株式会社 Bonded substrate manufacturing apparatus and the bonded substrate manufacturing method pasting
US20030233085A1 (en) 2002-06-18 2003-12-18 Pedro Giammarusti Optimization of transcutaneous active permeation of compounds through the synergistic use of ultrasonically generated mechanical abrasion of the skin, chemical enhancers and simultaneous application of sonophoresis, iontophoresis, electroporation, mechanical vibrations and magnetophoresis through single application devices
US20050287648A1 (en) * 2002-08-05 2005-12-29 University Of Rochester Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
US8001962B2 (en) * 2002-08-23 2011-08-23 Sheiman Ultrasonic Research Foundation Pty Ltd. Nebulizing and drug delivery device
EP1556061B1 (en) * 2002-10-04 2007-04-18 Photokinetix Inc Photokinetic delivery of biologically active substances using pulsed incoherent light
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
CA2552690C (en) * 2002-12-31 2014-12-09 Ultra-Sonic Technologies, L.L.C. Transdermal delivery using encapsulated agent activated by ultrasound and/or heat
US20040253304A1 (en) * 2003-01-29 2004-12-16 Yossi Gross Active drug delivery in the gastrointestinal tract
US20040267240A1 (en) * 2003-01-29 2004-12-30 Yossi Gross Active drug delivery in the gastrointestinal tract
US20040158194A1 (en) * 2003-02-06 2004-08-12 Wolff Andy And Beiski Ben Z. Oral devices and methods for controlled drug release
CA2545798A1 (en) * 2003-02-19 2004-09-02 Dermisonics, Inc. Ultrasonically enhanced saline treatment for burn damaged skin
US7052652B2 (en) 2003-03-24 2006-05-30 Rosedale Medical, Inc. Analyte concentration detection devices and methods
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
JP2004343275A (en) * 2003-05-14 2004-12-02 Murata Mach Ltd Image processing system and scanner
US7850621B2 (en) 2003-06-06 2010-12-14 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
NL1023720C2 (en) * 2003-06-23 2004-12-28 Univ Eindhoven Tech A method for modifying the transport properties of a material, method for releasing a drug from an implant, as well as implant with drug.
WO2005023985A3 (en) * 2003-09-03 2006-08-24 Stephen Dewhurst Cytidine deaminase activators, deoxycytidine deaminase activators, vif antagonists, and methods of screening for molecules thereof
WO2005033659A3 (en) 2003-09-29 2007-01-18 Pelikan Technologies Inc Method and apparatus for an improved sample capture device
WO2005037095A1 (en) 2003-10-14 2005-04-28 Pelikan Technologies, Inc. Method and apparatus for a variable user interface
WO2005065414A3 (en) 2003-12-31 2005-12-29 Pelikan Technologies Inc Method and apparatus for improving fluidic flow and sample capture
CA2553745A1 (en) 2004-01-21 2005-08-04 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
US8771183B2 (en) 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
US8158770B2 (en) * 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
EP1751546A2 (en) 2004-05-20 2007-02-14 Albatros Technologies GmbH & Co. KG Printable hydrogel for biosensors
US20070106138A1 (en) * 2005-05-26 2007-05-10 Beiski Ben Z Intraoral apparatus for non-invasive blood and saliva monitoring & sensing
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc Method and apparatus for a fluid sampling device
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US20060094945A1 (en) * 2004-10-28 2006-05-04 Sontra Medical Corporation System and method for analyte sampling and analysis
EP1827388A2 (en) * 2004-12-14 2007-09-05 E-Pill Pharma Ltd. Local delivery of drugs or substances using electronic permeability increase
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
US20060247601A1 (en) * 2005-04-19 2006-11-02 Ellin Philip J Method of improved drug delivery and for treatment of cellulitis
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
RU2007146596A (en) * 2005-05-19 2009-06-27 И-Пилл Фарма, Лтд. (Il) Ingestible device for producing nitric oxide in tissues
ES2369034T3 (en) * 2005-05-23 2011-11-24 Biosonic Australia Pty. Ltd. Apparatus for atomizing and liquid filtration.
US20060281187A1 (en) 2005-06-13 2006-12-14 Rosedale Medical, Inc. Analyte detection devices and methods with hematocrit/volume correction and feedback control
US7713218B2 (en) 2005-06-23 2010-05-11 Celleration, Inc. Removable applicator nozzle for ultrasound wound therapy device
US7785277B2 (en) * 2005-06-23 2010-08-31 Celleration, Inc. Removable applicator nozzle for ultrasound wound therapy device
US9101949B2 (en) * 2005-08-04 2015-08-11 Eilaz Babaev Ultrasonic atomization and/or seperation system
US20070031611A1 (en) * 2005-08-04 2007-02-08 Babaev Eilaz P Ultrasound medical stent coating method and device
US7896539B2 (en) * 2005-08-16 2011-03-01 Bacoustics, Llc Ultrasound apparatus and methods for mixing liquids and coating stents
EP2989981A1 (en) 2005-09-30 2016-03-02 Intuity Medical, Inc. Multi-site body fluid sampling and analysis cartridge
US8801631B2 (en) * 2005-09-30 2014-08-12 Intuity Medical, Inc. Devices and methods for facilitating fluid transport
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US8273071B2 (en) 2006-01-18 2012-09-25 The Invention Science Fund I, Llc Remote controller for substance delivery system
US8936590B2 (en) 2005-11-09 2015-01-20 The Invention Science Fund I, Llc Acoustically controlled reaction device
US8083710B2 (en) 2006-03-09 2011-12-27 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US20070106275A1 (en) 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Reaction device controlled by RF control signal
US7942867B2 (en) 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
US8992511B2 (en) 2005-11-09 2015-03-31 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US8273075B2 (en) 2005-12-13 2012-09-25 The Invention Science Fund I, Llc Osmotic pump with remotely controlled osmotic flow rate
JP2009516718A (en) * 2005-11-23 2009-04-23 ウニベルジテート チューリッヒ Allergy treatment by percutaneous allergen challenge
US7432069B2 (en) * 2005-12-05 2008-10-07 Sontra Medical Corporation Biocompatible chemically crosslinked hydrogels for glucose sensing
US20080177220A1 (en) * 2006-01-06 2008-07-24 The Curators Of The University Of Missouri Ultrasound-Mediated Transcleral Drug Delivery
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
EP2010276B1 (en) * 2006-04-26 2014-01-22 Covidien LP Multi-stage microporation device
US8562547B2 (en) 2006-06-07 2013-10-22 Eliaz Babaev Method for debriding wounds
US20080071157A1 (en) 2006-06-07 2008-03-20 Abbott Diabetes Care, Inc. Analyte monitoring system and method
US7431704B2 (en) * 2006-06-07 2008-10-07 Bacoustics, Llc Apparatus and method for the treatment of tissue with ultrasound energy by direct contact
US20090209899A1 (en) * 2006-06-15 2009-08-20 Harry Unger Delivery system and process
US8050752B2 (en) * 2006-09-29 2011-11-01 Bacoustics, Llc Method of treating lumens, cavities, and tissues of the body with an ultrasound delivered liquid
US20080082039A1 (en) * 2006-09-29 2008-04-03 Eilaz Babaev Ultrasound Liquid Delivery Device
WO2008136852A3 (en) 2006-11-01 2009-04-23 Ryan Patrick Bennett Methods and compositions related to the structure and function of apobec3g
US20080142616A1 (en) * 2006-12-15 2008-06-19 Bacoustics Llc Method of Producing a Directed Spray
WO2008079379A1 (en) * 2006-12-22 2008-07-03 Celleration, Inc. Apparatus to prevent applicator re-use
WO2008085911A1 (en) * 2007-01-04 2008-07-17 Celleration, Inc. Removable multi-channel applicator nozzle
US8491521B2 (en) * 2007-01-04 2013-07-23 Celleration, Inc. Removable multi-channel applicator nozzle
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
RU2444980C2 (en) * 2007-03-07 2012-03-20 Эко Терапьютикс, Инк. Transdermal system of analite monitoring and methods of analite detection
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US7753285B2 (en) 2007-07-13 2010-07-13 Bacoustics, Llc Echoing ultrasound atomization and/or mixing system
US7780095B2 (en) 2007-07-13 2010-08-24 Bacoustics, Llc Ultrasound pumping apparatus
WO2009046345A1 (en) * 2007-10-05 2009-04-09 Worthington, W. Bradley Magnetophoresis apparatus and method of use
EP2231279A1 (en) * 2007-12-28 2010-09-29 Celleration, Inc. Methods for treating inflammatory skin disorders
US20090177123A1 (en) * 2007-12-28 2009-07-09 Celleration, Inc. Methods for treating inflammatory disorders
WO2009126900A1 (en) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
EP2293719B1 (en) * 2008-05-30 2015-09-09 Intuity Medical, Inc. Body fluid sampling device -- sampling site interface
US20090299266A1 (en) * 2008-06-02 2009-12-03 Mattioli Engineering Ltd. Method and apparatus for skin absorption enhancement and transdermal drug delivery
CA2727015A1 (en) * 2008-06-04 2009-12-10 Coda Therapeutics, Inc. Treatment of pain with gap junction modulation compounds
CA2726067A1 (en) 2008-06-06 2009-12-10 Intuity Medical, Inc. Detection meter and mode of operation
US20100022919A1 (en) * 2008-07-22 2010-01-28 Celleration, Inc. Methods of Skin Grafting Using Ultrasound
US20110195501A1 (en) * 2008-08-06 2011-08-11 Pangu Gautam D Ultrasonically induced release from polymer vesicles
US9446227B2 (en) 2008-09-12 2016-09-20 Sonescence, Inc. Ultrasonic dispersion of compositions in tissue
US20100069827A1 (en) 2008-09-12 2010-03-18 Barry Neil Silberg Pre-Surgical Prophylactic Administration of Antibiotics and Therapeutic Agents
US20100222417A1 (en) * 2008-11-26 2010-09-02 Alnylam Pharmaceuticals Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissues
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8606366B2 (en) 2009-02-18 2013-12-10 Syneron Medical Ltd. Skin treatment apparatus for personal use and method for using same
WO2010127050A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US20110066175A1 (en) * 2009-05-07 2011-03-17 Rainbow Medical Ltd. Gastric anchor
US20100286587A1 (en) * 2009-05-07 2010-11-11 Yossi Gross Sublingual electrical drug delivery
US8414559B2 (en) * 2009-05-07 2013-04-09 Rainbow Medical Ltd. Gastroretentive duodenal pill
US20100286628A1 (en) * 2009-05-07 2010-11-11 Rainbow Medical Ltd Gastric anchor
WO2011013101A1 (en) 2009-07-30 2011-02-03 Alma Lasers Ltd. A sonotrode
US8523791B2 (en) * 2009-08-11 2013-09-03 Laboratoire Naturel Paris, Llc Multi-modal drug delivery system
EP2473099A4 (en) 2009-08-31 2015-01-14 Abbott Diabetes Care Inc Analyte monitoring system and methods for managing power and noise
EP2473098A4 (en) 2009-08-31 2014-04-09 Abbott Diabetes Care Inc Analyte signal processing device and methods
EP2482720A4 (en) 2009-09-29 2014-04-23 Abbott Diabetes Care Inc Method and apparatus for providing notification function in analyte monitoring systems
US8919605B2 (en) 2009-11-30 2014-12-30 Intuity Medical, Inc. Calibration material delivery devices and methods
CN103096976B (en) 2009-12-31 2016-04-27 杰拓奥兹有限公司 Portable ultrasound system
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
WO2013020103A1 (en) 2011-08-03 2013-02-07 Intuity Medical, Inc. Devices and methods for body fluid sampling and analysis
WO2013148736A1 (en) 2012-03-27 2013-10-03 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
JP2015520754A (en) 2012-05-18 2015-07-23 オタゴ イノベーション リミテッド Combination therapy and a composition for wound healing
EP2732832A3 (en) 2012-11-14 2015-07-01 Universitair Medisch Centrum Groningen (UMCG) Drug delivery device comprising an active compound and a thermo-sensitive polymeric material
US20140221877A1 (en) * 2013-02-01 2014-08-07 Moshe Ein-Gal Pressure-assisted irreversible electroporation
CN104107503B (en) * 2014-08-01 2017-03-22 北京中美联医学科学研究院有限公司 Low Intermediate Frequency modulation through an ultrasound drug delivery systems

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551554A (en) * 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US3711606A (en) * 1970-09-02 1973-01-16 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active steroidal agents with dmso
US3711602A (en) * 1970-10-30 1973-01-16 Crown Zellerbach Corp Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso
US4002221A (en) * 1972-09-19 1977-01-11 Gilbert Buchalter Method of transmitting ultrasonic impulses to surface using transducer coupling agent
US4144646A (en) * 1975-12-05 1979-03-20 Lion Hamigaki Kabushiki Kaisha Torsional ultrasonic vibrators
FR2336116B1 (en) * 1975-12-22 1980-04-30 Lion Hamigaki Kk
US4309989A (en) * 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
GB1577551A (en) * 1976-02-09 1980-10-22 Fahim M Medication for topical application by ultrasound
DE2756460A1 (en) * 1977-12-17 1979-06-21 Fraunhofer Ges Forschung Therapeutic substances application - using ultrasonic bursts to improve penetration into tissue
US4176664A (en) * 1978-03-13 1979-12-04 Stanley Kalish Impregnated bandage
US4280494A (en) * 1979-06-26 1981-07-28 Cosgrove Robert J Jun System for automatic feedback-controlled administration of drugs
US4249531A (en) * 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
CA1165240A (en) * 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4372296A (en) * 1980-11-26 1983-02-08 Fahim Mostafa S Treatment of acne and skin disorders and compositions therefor
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4563184A (en) * 1983-10-17 1986-01-07 Bernard Korol Synthetic resin wound dressing and method of treatment using same
US4557943A (en) * 1983-10-31 1985-12-10 Advanced Semiconductor Materials America, Inc. Metal-silicide deposition using plasma-enhanced chemical vapor deposition
US4646725A (en) * 1983-11-16 1987-03-03 Manoutchehr Moasser Method for treating herpes lesions and other infectious skin conditions
US4605670A (en) * 1984-02-01 1986-08-12 Nitto Electric Industrial Co., Ltd. Method for percutaneously administering metoclopramide
US4732153A (en) * 1984-07-18 1988-03-22 Michael Phillips Transdermal dosimeter
DK8601218A (en) * 1984-07-18 1986-03-17
US4834978A (en) * 1984-10-01 1989-05-30 Biotek, Inc. Method of transdermal drug delivery
US4698058A (en) * 1985-10-15 1987-10-06 Albert R. Greenfeld Ultrasonic self-cleaning catheter system for indwelling drains and medication supply
US4948587A (en) * 1986-07-08 1990-08-14 Massachusetts Institute Of Technology Ultrasound enhancement of transbuccal drug delivery
US4767402A (en) * 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
JPH0476994B2 (en) * 1986-11-21 1992-12-07 Tanabe Seiyaku Co
JPH0363913B2 (en) * 1986-11-26 1991-10-03 Toshiro Tachibana
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
EP0278599A3 (en) * 1987-02-02 1988-12-07 Seiko Epson Corporation Photographic transfer type image forming apparatus
US5312325A (en) * 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US4787888A (en) * 1987-06-01 1988-11-29 University Of Connecticut Disposable piezoelectric polymer bandage for percutaneous delivery of drugs and method for such percutaneous delivery (a)
US4780212A (en) * 1987-07-31 1988-10-25 Massachusetts Institute Of Technology Ultrasound enchancement of membrane permeability
US4821733A (en) * 1987-08-18 1989-04-18 Dermal Systems International Transdermal detection system
US4820720A (en) * 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
EP0398960B1 (en) * 1988-01-21 1995-12-06 Massachusetts Institute Of Technology Transport of molecules across tissue using electroporation
DE3803897C2 (en) * 1988-02-09 1989-11-16 Degussa Ag, 6000 Frankfurt, De
US5076273A (en) * 1988-09-08 1991-12-31 Sudor Partners Method and apparatus for determination of chemical species in body fluid
US5008110A (en) * 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
WO1990015568A3 (en) * 1989-06-02 1991-04-18 Charles Dewey Ebert Apparatus and methods for noninvasive blood glucose monitoring
US5139023A (en) * 1989-06-02 1992-08-18 Theratech Inc. Apparatus and method for noninvasive blood glucose monitoring
JP2788307B2 (en) * 1989-11-30 1998-08-20 住友ベークライト株式会社 Medicine administering device
US5140985A (en) * 1989-12-11 1992-08-25 Schroeder Jon M Noninvasive blood glucose measuring device
US5016615A (en) * 1990-02-20 1991-05-21 Riverside Research Institute Local application of medication with ultrasound
US5115805A (en) * 1990-02-23 1992-05-26 Cygnus Therapeutic Systems Ultrasound-enhanced delivery of materials into and through the skin
US5231975A (en) * 1990-02-23 1993-08-03 Cygnus Therapeutic Systems Ultrasound-enhanced delivery of materials into and through the skin
US5197946A (en) * 1990-06-27 1993-03-30 Shunro Tachibana Injection instrument with ultrasonic oscillating element
DE69215722D1 (en) * 1991-03-22 1997-01-23 Katsuro Tachibana Amplifier for ultrasonic therapy of diseases as well as those containing liquid pharmaceutical compositions
JP3181071B2 (en) * 1991-06-28 2001-07-03 俊郎 立花 Blood processing apparatus
US5171215A (en) * 1991-08-22 1992-12-15 Flanagan Dennis F Endermic method and apparatus
US5405614A (en) * 1992-04-08 1995-04-11 International Medical Associates, Inc. Electronic transdermal drug delivery system
NL9200731A (en) * 1992-04-22 1993-11-16 Jacob Korf A method and apparatus for non-invasively monitoring the concentration of substances in blood.
JPH0670987A (en) * 1992-08-28 1994-03-15 Katsuro Tachibana Medicine dosing and body liquid taking-out unit and device therefor
US5421816A (en) * 1992-10-14 1995-06-06 Endodermic Medical Technologies Company Ultrasonic transdermal drug delivery system
US5386837A (en) * 1993-02-01 1995-02-07 Mmtc, Inc. Method for enhancing delivery of chemotherapy employing high-frequency force fields
US5267985A (en) * 1993-02-11 1993-12-07 Trancell, Inc. Drug delivery by multiple frequency phonophoresis
CA2114968A1 (en) * 1993-02-25 1994-08-26 John Wille Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
US5667487A (en) * 1993-04-07 1997-09-16 Henley; Julian L. Ionosonic drug delivery apparatus
US5413550A (en) * 1993-07-21 1995-05-09 Pti, Inc. Ultrasound therapy system with automatic dose control
US5415629A (en) * 1993-09-15 1995-05-16 Henley; Julian L. Programmable apparatus for the transdermal delivery of drugs and method
US5458140A (en) * 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5445611A (en) * 1993-12-08 1995-08-29 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal delivery with ultrasound and chemical enhancers
US5443080A (en) * 1993-12-22 1995-08-22 Americate Transtech, Inc. Integrated system for biological fluid constituent analysis
US5833647A (en) * 1995-10-10 1998-11-10 The Penn State Research Foundation Hydrogels or lipogels with enhanced mass transfer for transdermal drug delivery

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7172859B2 (en) 2000-07-14 2007-02-06 Transform Pharmaceuticals, Inc. System and method for optimizing tissue barrier transfer of compounds
US20040087007A1 (en) * 2000-07-14 2004-05-06 Transform Pharmaceuticals, Inc. System and method for optimizing tissue barrier transfer of compounds
US6758099B2 (en) 2000-07-14 2004-07-06 Transform Pharmaceuticals, Inc. System and method for optimizing tissue barrier transfer of compounds
US20040235145A1 (en) * 2000-07-14 2004-11-25 Cima Michael J. Transdermal assay with magnetic clamp
US6852526B2 (en) 2000-07-14 2005-02-08 Transform Pharmaceuticals, Inc. Transdermal assay with magnetic clamp
US20040062780A1 (en) * 2002-10-01 2004-04-01 Keller Brian C. Compositions and methods useful for the reduction of fine lines and wrinkles
US7785623B2 (en) 2002-10-01 2010-08-31 Keller Brian C Compositions and methods useful for the reduction of fine lines and wrinkles
US7993109B2 (en) 2002-10-09 2011-08-09 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
US8029250B2 (en) 2002-10-09 2011-10-04 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
US7993108B2 (en) 2002-10-09 2011-08-09 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
US7922458B2 (en) 2002-10-09 2011-04-12 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
US8047812B2 (en) 2002-10-09 2011-11-01 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
US8047811B2 (en) 2002-10-09 2011-11-01 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
US8343093B2 (en) 2002-10-09 2013-01-01 Abbott Diabetes Care Inc. Fluid delivery device with autocalibration
US8029245B2 (en) 2002-10-09 2011-10-04 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
US20050208477A1 (en) * 2002-10-28 2005-09-22 Transform Pharmaceuticals, Inc. Raised surface assay plate
US20040142460A1 (en) * 2002-10-28 2004-07-22 Michael Cima Raised surface assay plate
US7449307B2 (en) 2002-10-28 2008-11-11 Transform Pharmaceuticals, Inc. Raised surface assay plate
US8512246B2 (en) 2003-04-28 2013-08-20 Abbott Diabetes Care Inc. Method and apparatus for providing peak detection circuitry for data communication systems
US7679407B2 (en) 2003-04-28 2010-03-16 Abbott Diabetes Care Inc. Method and apparatus for providing peak detection circuitry for data communication systems
US7763455B2 (en) 2003-05-16 2010-07-27 Transform Pharmaceuticals, Inc. Raised surface assay plate
US20070105185A1 (en) * 2003-05-16 2007-05-10 Cima Michael J Raised surface assay plate
EP1706176A4 (en) * 2004-01-09 2008-06-25 Alza Corp Frequency assisted transdermal agent delivery method and system
EP1706176A2 (en) * 2004-01-09 2006-10-04 Alza Corporation Frequency assisted transdermal agent delivery method and system
US7537590B2 (en) 2004-07-30 2009-05-26 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
US8403915B2 (en) 2004-09-01 2013-03-26 Microchips, Inc. Multi-opening reservoir devices for controlled release or exposure of reservoir contents
US8029459B2 (en) 2005-03-21 2011-10-04 Abbott Diabetes Care Inc. Method and system for providing integrated medication infusion and analyte monitoring system
US8029460B2 (en) 2005-03-21 2011-10-04 Abbott Diabetes Care Inc. Method and system for providing integrated medication infusion and analyte monitoring system
US8343092B2 (en) 2005-03-21 2013-01-01 Abbott Diabetes Care Inc. Method and system for providing integrated medication infusion and analyte monitoring system
US8089363B2 (en) 2005-05-17 2012-01-03 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
US8653977B2 (en) 2005-05-17 2014-02-18 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
US7768408B2 (en) 2005-05-17 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
US9332944B2 (en) 2005-05-17 2016-05-10 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
US8471714B2 (en) 2005-05-17 2013-06-25 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
US7884729B2 (en) 2005-05-17 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
US9750440B2 (en) 2005-05-17 2017-09-05 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
US8112138B2 (en) 2005-06-03 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US7756561B2 (en) 2005-09-30 2010-07-13 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US8638220B2 (en) 2005-10-31 2014-01-28 Abbott Diabetes Care Inc. Method and apparatus for providing data communication in data monitoring and management systems
US8344966B2 (en) 2006-01-31 2013-01-01 Abbott Diabetes Care Inc. Method and system for providing a fault tolerant display unit in an electronic device
US9064107B2 (en) 2006-10-31 2015-06-23 Abbott Diabetes Care Inc. Infusion devices and methods
US8579853B2 (en) 2006-10-31 2013-11-12 Abbott Diabetes Care Inc. Infusion devices and methods
US8560082B2 (en) 2009-01-30 2013-10-15 Abbott Diabetes Care Inc. Computerized determination of insulin pump therapy parameters using real time and retrospective data processing
US8467972B2 (en) 2009-04-28 2013-06-18 Abbott Diabetes Care Inc. Closed loop blood glucose control algorithm analysis
US8798934B2 (en) 2009-07-23 2014-08-05 Abbott Diabetes Care Inc. Real time management of data relating to physiological control of glucose levels
WO2016004442A3 (en) * 2014-07-03 2016-03-31 Redding Bruce K Jr Method and apparatus for measuring the dose remaining upon a transdermal drug delivery device

Also Published As

Publication number Publication date Type
US20040210184A1 (en) 2004-10-21 application
US6041253A (en) 2000-03-21 grant

Similar Documents

Publication Publication Date Title
Henry et al. Microfabricated microneedles: a novel approach to transdermal drug delivery
Barry Breaching the skin's barrier to drugs
Prausnitz Microneedles for transdermal drug delivery
US5667491A (en) Method for rapid temporal control of molecular transport across tissue
Cevc Transdermal drug delivery of insulin with ultradeformable carriers
Barry Is transdermal drug delivery research still important today?
US5279543A (en) Device for iontophoretic non-invasive sampling or delivery of substances
Machet et al. Phonophoresis: efficiency, mechanisms and skin tolerance
US7066884B2 (en) System, method, and device for non-invasive body fluid sampling and analysis
US5302172A (en) Method and composition for iontophoresis
US7328064B2 (en) Electroporation device and injection apparatus
US6532386B2 (en) Electrotransort device comprising blades
US7133717B2 (en) Tissue electroperforation for enhanced drug delivery and diagnostic sampling
Polat et al. Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends
US7113821B1 (en) Tissue electroperforation for enhanced drug delivery
Kumar et al. Modified transdermal technologies: Breaking the barriers of drug permeation via the skin
US5458140A (en) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US6585678B1 (en) Booster for therapy of disease with ultrasound and pharmaceutical IDLIQU composition containing the same
US6022316A (en) Apparatus and method for electroporation of microporated tissue for enhancing flux rates for monitoring and delivery applications
US6419642B1 (en) Irradiation enhanced permeation and delivery
Teo et al. In vitro and in vivo characterization of MEMS microneedles
Le et al. Combined effect of low-frequency ultrasound and iontophoresis: applications for transdermal heparin delivery
US7335377B2 (en) Transdermal delivery system for dried particulate or lyophilized medications
US5582586A (en) Drug administration and humor sampling unit and an apparatus therefor
US20050137536A1 (en) Microneedle with membrane